Brightseed unveils “world-first” clinically validated AI platform for plant bioactives discovery
Key takeaways
- Brightseed has launched an AI-driven innovation platform to help health science companies discover, validate, and commercialize plant-based bioactive compounds.
- The proprietary Forager engine analyzes over 11 million natural compounds to reduce R&D fragmentation and accelerate the journey from discovery to market.
- Recent platform successes include the development of ingredients for glucose stabilization and gut health to meet rising consumer demand for bioactive products.
Specializing in the AI-driven discovery of new plant bioactives, Brightseed has launched an Innovation Platform to help convey more information about these novel ingredients and their health benefits for product applications. It is designed to accelerate the development and commercialization of products containing these clinically validated compounds — accelerating their pathway to market.
Brightseed has dubbed its core proprietary AI-powered discovery engine, Forager, the world’s largest proprietary bioactive data bank. It spans more than 11 million natural compounds across 23 health territories.
Positioning itself apart from general AI systems trained on public data, Brightseed’s platform harnesses the company’s own proprietary biological intelligence “designed specifically for scientific rigor, traceability, and defensibility.”
“Health innovation has operated on a broken probability curve for decades,” says Lee Chae, Ph.D., co-founder and CEO of Brightseed. “We built the Brightseed Innovation Platform to fundamentally change that curve.”
“By converging deep biological insight, proprietary multi-omics data assets, and cutting-edge AI and machine learning architecture into a continuous innovation foundation, we are defining a new category — one where AI is not an add-on, but the core operating foundation of life sciences innovation.”
Tackling fragmented R&D
Across health and life sciences, Brightseed underlines that more than 75% of early product ideas fail to reach market due to fragmented workflows, disconnected data, and late-stage risk discovery.
“Innovation has historically been structured as episodic project work rather than a connected, compounding capability,” highlights the company.
The Brightseed Innovation Platform is designed to connect discovery, development, and commercialization within a “unified architecture” that preserves scientific insight, evidence, and decision context across the innovation lifecycle.
One recently discovered naturally occurring bioactive blend – which Brightseed commercialized as its ingredient BioMetaControl — was found to potentially stabilize glucose levels among adults weaning off GLP-1 medications, while improving glycemic control markers in prediabetic adults.
BioMetaControl launched following Brightseed’s release of the ingredient Bio Gut Core, which is designed to strengthen the gut barrier and provide relief from bloating and belly pain.
Expanding partnerships
Brightseed leverages Rapid Profiling to quickly supply actionable insights on ingredients’ phytochemical and bioactive composition in six to eight weeks, which accelerates the clinical validation and commercialization process.
With more than 40 partnerships across consumer health, nutrition, personal care, pharmaceuticals, and animal health, the company is transitioning its clients toward a recurring subscription model on its platform.
Previously, Brightseed and UK-based consumer healthcare business Haleon joined forces to advance the discovery of plant-based, small molecules that can improve human health.
The Innovation Platform’s launch is timely, as Brightseed highlights that consumers are willing to pay more for products containing bioactives. Its latest market research indicates that “bioactivists” are the largest and fastest-growing health segment among US consumers, growing from 27% to 45% between 2022 and 2025.
